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To allow genome-scale identification of genes that
regulate cellular signaling, we cloned >90% of all hu-
man full-length protein kinase cDNAs and constructed
the corresponding kinase activity-deficient mutants.
To establish the utility of this resource, we tested the
effect of expression of the kinases on three different
cellular signaling models. In all screens, many kinases
had a modest but significant effect, apparently due
to crosstalk between signaling pathways. However,
the strongest effects were found with known regula-
tors and novel components, such as MAP3K10 and
DYRK2, which we identified in a mammalian Hedge-
hog (Hh) signaling screen. DYRK2 directly phosphory-
lated and induced the proteasome-dependent degra-
dation of the key Hh pathway-regulated transcription
factor, GLI2. MAP3K10, in turn, affected GLI2 indi-
rectly by modulating the activity of DYRK2 and the
known Hh pathway component, GSK3b. Our results
establish kinome expression screening as a highly ef-
fective way to identify physiological signaling pathway
components and genes involved in pathological
signaling crosstalk.
INTRODUCTION
Protein kinases are one of the largest families of genes in eukary-
otes: approximately 2% of all human genes have protein kinase
domain(s) (Venter et al., 2001). Protein kinases mediate most of
the signal transduction events in cells by phosphorylation of spe-
cific substrates—modifying their activity, cellular location, and/orassociation with other proteins. Mammalian protein kinases can
be divided into tyrosine kinases, serine/threonine kinases, and ki-
nases that can phosphorylate both tyrosine and serine/threonine
residues. Despite these differences in substrate specificity, all
known mammalian protein kinases have structurally similar
kinase domains (Huse and Kuriyan, 2002; Nolen et al., 2004).
The kinase domain is composed of 250–300 amino acid resi-
dues and can be divided into two subdomains, a smaller N
lobe and a larger C lobe, between which is the cleft into which
ATP and substrates bind (Huse and Kuriyan, 2002; Nolen et al.,
2004). The relatively strong conservation of kinase domains
has allowed the computational characterization of the protein ki-
nase complement of the human genome (the kinome), and for
most kinases, also the identification of critical residues required
for their catalytic activity (Manning et al., 2002). These residues
include a lysine (Lys72 in PKA) in the N lobe, which is required
for proper orientation of ATP, and an aspartate (Asp166 in
PKA) in the catalytic loop, which interacts with the hydroxyl
side chain of the substrate (Huse and Kuriyan, 2002). Mutations
in these residues kill the catalytic activity of kinases (Manning
et al., 2002), but do not interfere with substrate recognition or
binding to other proteins. As a result, catalytically inactive kinase
can either have no activity, or dominant-negative activity due
to titration of cofactors from the corresponding active kinase
(Mendenhall et al., 1988).
Protein kinases are the most common class of genes among
known cancer genes. In most cases, cancer is associated with in-
crease in activity of specific kinases caused by mutational activa-
tion, or increase in expression due to gene amplification or trans-
location (Futreal et al., 2004). In a recent study, 23% (120/518)
of kinase genes were estimated to function as cancer genes
(Greenman et al., 2007). An unexpectedly large number of ki-
nases were found to be mutated, but in many cases at a relatively
low frequency, suggesting that either a large number of kinaseCell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc. 537
pathways can contribute to cancer or that many kinases can
regulate the same pathways when activated unphysiologically.
To allow unbiased genome-wide analysis of crosstalk be-
tween kinase pathways and the role of kinases in cellular signal-
ing, we developed a collection of >93% of full-length human pro-
tein kinase cDNAs. Because increased kinase expression often
leads to gain-of-function phenotypes due to increased activity,
this collection could be used to systematically screen for kinases
affecting a given cellular phenotype. However, because overex-
pression can also lead to loss-of-function effects due to scaf-
folding or other nonenzymatic functions of kinases, we also gen-
erated a corresponding set of catalytically inactive kinases,
which can be used to test whether the kinase activity is required
for the observed phenotypes. To test the utility of this resource,
we performed a set of screens designed to identify novel kinases
affecting oncogenic signaling pathways.
Of particular interest to us was the Hh signaling pathway (Var-
josalo and Taipale, 2007), because it has been linked to several
forms of human cancer (Rubin and de Sauvage, 2006). In addi-
tion, we and others have recently found that some components,
including the protein kinase Fused, that regulate this signaling
pathway in invertebrate model organisms do not affect Hh
signaling in mammals (Chen et al., 2005; Cooper et al., 2005;
Merchant et al., 2005; Svard et al., 2006; Varjosalo et al.,
2006), suggesting that kinases distinct from Fused regulate
Shh (Sonic hedgehog, a mammalian ortholog of Hh) pathway ac-
tivity. To identify such kinases, we screened the kinase collection
in a cell-culture model of Shh signaling, finding two novel kinases
regulating the Shh pathway, DYRK2 and MAP3K10. Both of
these kinases were also required for Shh signaling, as revealed
by a kinome-wide siRNA screen. Using cell lines deficient in dif-
ferent components of the Shh pathway, we further mapped the
activities of these kinases to the GLI transcription factors, and
showed that they are required for pathway function in cultured
cells and also affected Shh signaling in vivo.
To further validate the kinome resource, and to test the speci-
ficity of the kinases identified as Shh effectors, we also performed
two other screens: a TGFb signaling screen and a screen for ac-
tivators of replication of latent Kaposi’s sarcoma herpes virus
(KSHV). Whereas the TGFb screen identified only known effec-
tors, the KSHV screen linked a novel kinase, PIM1, to activation
of virus replication. Upon treatment of cells with viral activators,
PIM1 expression was induced, and the kinase associated with
and phosphorylated the KSHV latency-associated nuclear anti-
gen 1 (LANA-1), resulting in activation of lytic gene expression.
These results show that the genome-wide collection of protein-
kinase cDNAs we describe here can be used to systematically
and quantitatively analyze signaling crosstalk, and also to identify
novel regulatory kinases in multiple cellular signaling models.
RESULTS
Generation of Kinome-wide Expression-Ready
cDNA Library
The initial set of full-length kinase cDNAs were isolated from
800,000 individual sequenced cDNA clones derived from 20
different tissues. Subsequently, cDNAs for the kinases that
were not identified by brute force sequencing were isolated by538 Cell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc.PCR screening of pooled and plated libraries (Figure 1A; Table
S1). The resulting 568 genome-wide full-length kinome cDNA
array constructs are based on the pCMV6-XL vector (GenBank:
AF067196) that contain a CMV promoter, and a SV-40 origin of
replication for episomal replication and very strong overexpres-
sion in cells expressing the SV-40 large T antigen (e.g., 105–106
proteins/cell in COS1 cells) (Taipale et al., 2002). In cells lacking
SV-40T, the vector does not replicate, but the efficient CMV pro-
moter leads to the expression of proteins at moderate to high
levels (e.g., 103–104 proteins/cell) (Taipale et al., 2002), resulting
in overexpression of most nonstructural proteins.
We next used direct PCR to attempt to clone all of the remaining
kinases from five separate sources of cDNA, representing 48 dif-
ferent tissues and 34 unique cell lines. Using this approach, 16
more kinases were cloned, bringing the total to 93% of all human
kinases identified in silico (Manning et al., 2002). Analysis of the re-
maining 36 kinase ORFs, which we could not clone, revealed that
many of these were of very large size (13 are >1500 aa, including
titin and obscurin), or were expressed at very low or neglible levels
or in a very narrow range of tissues (15 kinases; Table S1). Failure
to clone the remaining kinases could also be due to toxicity in
E.coli, or problems with gene annotation. Three kinases are not
included in current ENSEMBL gene annotation, and there is no
experimental evidence to support the in silico predicted human
full-length ORFs for 26 of the 36 remaining kinases (Table S1).
Taken together, the resulting human kinome collection
consists of 568 cDNAs, representing 480 different kinases. The
representation of the different kinase subfamilies defined by
Manning et al. (2002) are shown in Figure 1B.
Analysis of Splice Forms and Protein Expression
Many kinases have alternatively spliced forms, some of which
code for functionally distinct, truncated and/or inactive proteins.
To address whether the splice forms present in our collection are
representative of the active kinome, we identified known protein
domains contained in the splice forms found in our collection,
and compared these to domains found in all splice forms of
the same kinases. Based on ENSEMBL annotations, we could
identify 1484 potential splice forms for our kinase clones, con-
taining a total of 1725 protein domains. The clones of our collec-
tion contained the vast majority (1692; 98.1%) of these domains
(see Supplemental Database).
The initial clone collection contains native untagged kinases,
ensuring wild-type activity, but making protein analyses depen-
dent on antibodies, which exist only against a minority of
kinases. To validate that the constructs express protein, we per-
formed an unbiased sampling using all immunohistochemistry-
grade kinase antibodies available from one supplier. Of 18 tested
constructs, 12 expressed protein (Figure 1C), and expression of
the remaining 6 could not be verified due to nonreactivity of the
antibody (nonreactivity against V5-tagged kinases; not shown).
To analyze a larger sample, we transferred 328 kinase ORFs
lacking stop codons to a Gateway recombination cloning entry
vector and moved 212 of these to a recipient vector containing
a C-terminal triple-V5 epitope tag (Table S1), and tested the
expression of this unbiased subset in COS1 cells. Transfection
of eight of these constructs was toxic to COS1 cells.
Dot-immunoblot analysis indicated that of the remaining 204
Figure 1. Kinase Cloning
(A) cDNAs were identified by screening master plates containing 5000 clones/well by PCR followed by subsequent PCR screening of lower-density subplates.
(B) Coverage of kinases in different subclasses (Manning et al., 2002).
(C) Validation of cDNA expression. cDNA expressing (white arrowheads) and nonexpressing (yellow arrows) COS1 cells were identified by specific antibodies
against the indicated kinases (red staining; DNA is stained blue).
(D) Dot immunoblot of lysates of COS1 cells expressing 212 kinases with C-terminal triple-V5 tags. Mock-transfected controls (blue box), kinases with clear
toxicity (red circles), and nonexpressing kinases (red asterisk) are indicated.
(E) Kinase cDNAs (left) were mutated using site-directed mutagenesis to generate kinase-deficient constructs (right). Mutated residues (red) in active-site motifs
are indicated. Lower conservation is indicated by x. Inset shows kinase assays of COS1 cell-expressed active and inactivated kinases. For identities of kinases in
(C)–(E), see Table S1.constructs, 201 (98.5%) expressed protein at detectable level,
and 3 (1.5%) failed to express (Figure 1D).
Taken together, these analyses indicate that the kinase collec-
tion cDNAs contain nearly all annotated protein domains found in
the respective genes, and that the vast majority of the kinase
constructs tested express full-length protein.
Generation of Catalytically Inactive Kinase
cDNA Collection
Kinase expression can affect cellular phenotype due to in-
creased catalytic activity or due to scaffolding or other functionsof the kinase protein. To differentiate between these possibilities,
kinases with active site mutations are commonly used; however,
no large collection of such inactive kinases is available. To facil-
itate the downstream analysis of the kinases identified in various
screens, we designed oligonucleotides for site-directed muta-
genesis of critical residues of the kinase domains of all the
kinases that were predicted to be catalytically active (Table S2)
and performed high-throughput mutagenesis. The resulting cat-
alytically inactive kinome library (Table S2) contains 425 kinase
cDNAs, representing 351 unique inactive kinases. Of these,
390 (316 unique kinases) were generated by mutagenesis, andCell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc. 539
Figure 2. Kinase cDNA and RNAi Screen for Novel Shh Pathway Components
(A and B) Effect of kinase expression on Shh pathway activity in the absence (A) or presence (B) of ShhN. Samples are sorted by phenotypic score. Red bars
indicate means, and black bars ±3 SD calculated from control samples (99.7% confidence, <1 false positive sample expected above and below 3 SD). Samples
that significantly differ from the mean are indicated by darker color; names of the kinases with strongest activities are also shown. Insets (top right) show ranks of
MAP3K10, PRKACB, and DYRK2 in corresponding screens performed using kinase-deficient constructs.
(C) MAP3K10 is required for Shh signaling. An x-y plot of results from kinome cDNA (y axis) and RNAi (x axis) screens that illustrates positive regulators of the Shh
pathway.
(D) DYRK2 is required for Shh signaling. An x-y plot of kinome cDNA and RNAi screens that illustrates negative regulators of the Shh pathway. The two data points
for DYRK2 are due to the presence of a single siRNA pool but two different cDNA constructs in the respective screens. Note that MAP3K10 and DYRK2 are strong
effectors in both cDNA and RNAi screens. For numerical data, see Tables S3 and S4. Error bars indicate 1 SD (n = 3).in the remaining 35 cases, the wild-type kinase lacks critical cat-
alytic residues and is predicted to be inactive. In most of the mu-
tant kinases (313 of 316), the lysine in the ‘‘VAIK’’ motif (Lys72 of
PKA) (Manning et al., 2002) was mutated to methionine (Fig-
ure S1). If the lysine was absent or could not be unequivocally
identified (three kinases), the aspartate in the ‘‘HRD’’ motif
(Asp166 of PKA) was mutated to alanine.
To validate the activity of the kinase collection and to confirm
effectiveness of the kinase-inactivating mutations, we analyzed
an unbiased sample consisting of 84 pairs of wild-type and mu-
tant kinases expressed in COS1 cells by in vitro kinase assays.
Eighty-two percent of the wild-type kinase precipitates had de-
tectable kinase activity (Table S2). This is likely an underestimate
of the fraction of active kinases, as specific substrates for most
kinases are not known. Specificity of kinases is illustrated by the
fact that a smaller fraction (70%) of the kinases had autophos-
phorylation activity, and only 19% displayed activity toward540 Cell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc.a commonly used substrate (casein). Ninety-five percent of ki-
nases showing robust activity in wild-type form were inactivated
by the lysine mutation (Table S2; Figure 1E).
A Large Fraction of All Kinases Significantly
Affect Shh Signaling
To test the utility of the kinome resource for identifying novel
genes relevant to cancer, we applied it to overexpression
screening in multiple cell-based models. We first analyzed Shh
signaling in NIH 3T3 cells (Taipale et al., 2000) by transfecting
the cells in triplicate with each kinase expression construct
together with the Shh-responsive reporter GLI-Luc (Taipale
et al., 2002). Analysis of the data revealed that 320 kinase con-
structs significantly (± 3 standard deviation [SD]) affected either
the uninduced or Shh-induced pathway activity (Figures 2A
and 2B; Table S3). In addition to PKA (Kalderon, 2005), it has
been previously suggested on the basis of overexpression
experiments that mammalian Hh signaling is specifically affected
by four protein kinases: DYRK1, PKCd, ERK-1, and AKT/PKB
(Mao et al., 2002; Riobo et al., 2006a, 2006b). Of these, we did
not observe an effect by overexpression of PKCd, but found
that ERK-1, AKT1, and DYRK1 class kinase (DYRK1B) had
statistically significant effects on Shh signaling (Table S3). The
effect of DYRK1B was relatively strong, whereas >90 kinases
had equal or stronger activity than ERK-1 or AKT1.
Relatively Few Kinases Have Strong Effect
on Shh Signaling
Although many kinases had small but significant effects on Shh-
specific reporter, expression of only four kinases—MAP3K10,
PKA, STK23, and PIM1—resulted in reporter activity that was
more than 75% of that induced by Shh, and only one kinase,
DYRK2, inhibited Shh-induced reporter activity more than
75%. Importantly, PKA, which depending on the dose either
positively or negatively affects Hh signaling in Drosophila (Zhou
et al., 2006), was among the strongest effectors. STK23 and
PIM1, but not MAP3K10 or DYRK2, also activated a mutant
GLI site-containing reporter (Figure S2A), indicating that their
effects on the reporter activity were not mediated by the Shh
pathway.
We next analyzed whether the kinase activities of MAP3K10
and DYRK2 were required for their activity by transfecting the
catalytically inactive kinome collection to NIH 3T3 cells together
with the GLI-Luc reporter. This analysis revealed that the kinase
activities of both MAP3K10 and DYRK2 were critical for their
ability to regulate the Shh pathway (insets in Figures 2A and
2B; Figure S2B).
To test whether the kinases were necessary for normal Shh
pathway function, we screened a siRNA library targeting the
mouse kinome in Shh-LIGHT2 cells (Taipale et al., 2000) in the
presence and absence of Shh. siRNAs targeting Map3k10 de-
creased the level of Shh-induced pathway activity (Figure 2C),
whereas siRNAs targeting Dyrk2 resulted in activation of the
Shh pathway in the absence of ligand (Figure 2D), indicating
that both kinases are required for Shh signaling. The siRNA
data were further validated using shRNA constructs to rule out
off-target effects (Figure S2C).
Analysis of Signaling Specificity
To test the specificity of the kinases, we performed a similar
screen to identify cellular kinases that activate lytic replication
of a latent tumor virus KSHV—the causative agent of Kaposi’s
sarcoma and primary effusion lymphoma (Cesarman et al.,
1995; Chang et al., 1994). To perform the screen, the kinases
were transfected to Vero cells infected with a recombinant
KSHV expressing RFP from the lytic PAN promoter (Vieira and
O’Hearn, 2004), and viral reactivation was primed by expression
of the viral transactivator RTA from a baculoviral vector. Quanti-
fication of the RFP intensities revealed that only one kinase,
PIM1, induced viral reactivation in two independent experiments
(Figure 3A). Conversely, kinase-deficient PIM1 acted in a domi-
nant-negative fashion, decreasing the basal level of reactivation
(Figure 3A). In addition, a chemical stimulator of viral reactivation,
sodium butyrate, induced expression of endogenous PIM1, and
association of PIM-1 with LANA-1, a protein that is required formaintenance of viral latency. PIM1 also phosphorylated LANA-
1, resulting in activation of viral lytic gene expression (Figure 3B).
These results suggest that PIM1 mediates viral reactivation via
phosphorylation of LANA-1.
To further establish the specificity of the screening method, we
performed another luciferase reporter-based screen to identify
effectors of TGFb signaling in mink lung Mv1Lu cells (Dennler
et al., 1998). The kinases with the strongest effects in this screen
were clearly distinct from those identified in the Shh and KSHV
screens, and included type I and type II receptors (Massague
et al., 2005) for activin and TGFb (Figures 3C and 3D; Table
S5). Taken together, the three kinome-wide screens clearly es-
tablish that although many kinases can cause crosstalk when
overexpressed, the strongest effectors identified are specific.
Thus, expression screening can be used to identify both known
and novel kinases affecting cellular signaling processes.
Validation of Shh Pathway-Specific Effects
of DYRK2 and MAP3K10
We next set out to further characterize the mechanism of action
of the novel kinases affecting the Shh pathway, DYRK2 and
MAP3K10. First, we determined their expression pattern by sys-
tematic analysis of existing microarray expression data. This
analysis revealed that these kinases are expressed in most nor-
mal tissues analyzed; MAP3K10 expression is highest in the lym-
phatic system, heart and bone marrow, whereas DYRK2 expres-
sion is strong in lymphatic system and in muscle-rich tissues,
such as skeletal muscle and heart (Figure 3E; Table S6). The sub-
cellular localization of GFP-tagged biologically active DYRK2
and MAP3K10 was cytoplasmic, suggesting that they regulate
a cytoplasmic component of the Shh pathway (Figure S3).
DYRK2 and MAP3K10 Have a Role in Shh
Signaling In Vivo
To test whether DYRK2 and MAP3K10 also affect the Shh path-
way in vivo, we expressed them in chick neural plate using in ovo
electroporation, and analyzed their effect on Shh signaling using
well-described markers (Jacob and Briscoe, 2003) for cells ex-
posed to high (FoxA2+), medium (Nkx2.2+), or low (Pax7) levels
of Shh (Figures 4A–4I and S3). Expression of MAP3K10 induced
high levels of Shh signaling, as indicated by its ability to induce
ectopic dorsal expression of FoxA2 (Figures 4D–4F and S3).
Expression of DYRK2, in contrast, suppressed Shh signaling,
as indicated by its ability to block ventral expression of Nkx2.2
(Figure 4J). These results indicate that MAP3K10 and DYRK2
can affect the Shh pathway both in cultured NIH 3T3 fibroblasts
and in developing neural cells in vivo.
DYRK2 and MAP3K10 Act at the Level
of the GLI Transcription Factors
To genetically map where these kinases act on the Shh pathway,
we used cells overexpressing or deficient in specific Shh pathway
components. First, we tested the ability of these kinases to func-
tion in cells where the transducing component of the Shh recep-
tor, Smo, was hyperactive or genetically ablated. DYRK2 could
inhibit the Shh pathway in the presence of oncogenically acti-
vated Smo (SmoA1) (Taipale et al., 2000) (Figure S4A), suggesting
that it acts at or downstream of Smo. Similarly, MAP3K10 wasCell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc. 541
Figure 3. Specificity of Overexpression Screening
(A–D) Three different kinome screens identify distinct kinases as strongest effectors, indicating that the effects of the overexpression of MAP3K10 and DYRK2 are
specific for the Shh pathway. In (A), a kinome screen identifies PIM1 as an inducer of reactivation of latent KSHV. Note that kinase-deficient PIM1-K67M fails to
reactivate KSHV.
(B) Sodium butyrate, a chemical inducer of viral reactivation, induces PIM1, which binds to and phosphorylates LANA-1. In the top panel, both sodium butyrate
and PIM1 expression induce red fluorescent protein (RFP) expression from viral lytic promoter. In the middle panels, sodium butyrate induces PIM1 expression.
In the bottom panels, pull-down western and IP kinase assays indicate that sodium butyrate increases PIM1 association with LANA-1 and phosphorylation of
LANA-1 by PIM1.
(C) Several known type I and type II activin and TGFb receptors (red) are identified in a kinome-wide activin/TGFb screen. Note that Shh screen hits (green) or BMP
receptor kinases (yellow) are not among the strongest effectors.
(D) Similar analysis reveals that the TGFb screen hits (red) do not affect the Shh pathway reporter.
(E) Analysis of the expression of the identified novel kinases (PIM1, MAP3K10, and DYRK2) in 18 different tissues, compared to 350 other kinases (top). Red
indicates high expression and green low or no expression (see Table S6).found to act downstream of Smo, as it could activate the Shh
pathway in Smo-deficient cells (Figure 5A).
Next, we tested whether the kinases act at the level of the GLI
transcription factors. Both kinases could modulate the ability of
overexpressed Gli2 and GLI1 to induce the Shh pathway (Fig-
ures S4B and S4C), and they also could affect activity of GLI in
cells lacking the GLI-inhibitory protein SuFu (Figure 5B). These
results indicate that both kinases act genetically at the level of
GLI. Consistently with the same level of action in the Shh path-
way, MAP3K10 and DYRK2 dose-dependently inhibited each
others’ effect on GLI activity (not shown).
MAP3K10 Modulates the Activity of Gli2 via
Regulation of DYRK2 and GSK3b
To further analyze the mechanism by which the kinases act, we
tested whether they affect the activity of the transcriptional acti-
vator domain of GLI. MAP3K10 failed to further induce transcrip-542 Cell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc.tional activity of Gli2 fused to the hyperactive transcriptional
activator domain of herpesvirus VP16 (GLI2-VP16) (Figure 5C),
indicating that it activates wild-type Gli2 by activating its tran-
scriptional activator domain. In contrast, DYRK2 was able to
inactivate also GLI2-VP16 (Figure 5C).
To analyze whether the effect of the kinases on GLI activity
was direct, we tested whether coexpression of MAP3K10 or
DYRK2 with Gli2 or GLI3 in COS1 cells resulted in phosphoryla-
tion of the GLIs. Whereas DYRK2 clearly induced a migration
shifts characteristic of phosphorylation, MAP3K10 had no de-
tectable effect on the migration of Gli2 or GLI3 (Figure 5D). To
test whether Gli2 is a substrate for DYRK2 or MAP3K10, we
used purified kinases in in vitro kinase assays using purified
TAP-tagged GLI2 as a substrate. DYRK2 efficiently phosphory-
lated TAP-GLI2, whereas MAP3K10 failed to do so (Figure 5E).
To identify MAP3K10 binding partners and substrates, biotiny-
lated MAP3K10, and MAP3K10 in the presence of g33P-ATP
Figure 4. Validation of the Novel Shh
Pathway Components
(A–J) MAP3K10 and DYRK2 affect Shh signaling in
vivo. Shown are confocal images of antibody-
stained sections from neural tubes of chick
embryos electroporated with GFP control vector
(A–C) or vector coexpressing GFP with activated
Smo (SmoA1; G–I), MAP3K10 (D–F), or DYRK2
(J). Note that expression of MAP3K10 or SmoA1
induces ectopic FoxA2 expression (arrowheads),
whereas expression of DYRK2 suppresses en-
dogenous Nkx2.2 (arrows). In all panels, ventral
side is down. To clearly show individual cells,
a merged image of ventral neural tube is shown
in (J).were used to probe-spotted protein microarrays containing 8265
human proteins (Hall et al., 2007). Proteins that bound the high-
est amount of biotinylated MAP3K10 per mass included DYRK2,
and the known Shh pathway regulatory kinases GSK3b, CK1a,
and CK13 (Figure 5F; Table S7). DYRK2 was also phosphorylated
by MAP3K10 (Figure 5F); the very high autophosphorylation
activity of GSK3b, CK1a, and CK13 potentially masked phos-
phorylation by MAP3K10 (Table S7). In kinase assays, purified
MAP3K10 increased the activity of GSK3b, but had no effect
on activities of CK1a and CK13 against a casein substrate
(Figure 5G).
We further mapped the phosphorylation sites of MAP3K10 on
DYRK2 by liquid chromatography-mass spectrometry (LC/MS).
Two phosphorylation sites were identified (Figure 5H), including
the conserved (Figure S5) threonine 308 in the activation loop.
This residue is directly adjacent to tyrosine 309, a critical activat-
ing autophosphorylation site found in all DYRK kinases (Fig-
ure S6) (Lochhead et al., 2005).
DYRK2 Directly Phosphorylates GLI Proteins
and Promotes Their Proteolytic Processing
DYRK2 has been reported to act as a priming kinase to CK1 and
GSK-3b (Gwack et al., 2006; Nishi and Lin, 2005) in controlling
ubiquitin-mediated degradation of NFAT and OMA-1. CK1 and
GSK-3b (Jia et al., 2002; Lum et al., 2003; Price and Kalderon,
2002) have also been linked to the regulation of processing of
the Drosophila GLI ortholog Ci, suggesting that DYRK2 may
act by initiating the phosphorylation events that lead to ubiquiti-
nylation and degradation of Gli2 (Pan et al., 2006), the major tran-
scriptionally activating GLI isoform in NIH 3T3 cells (Varjosalo
et al., 2006). DYRK2 and GLI could be coexpressed in COS1
cells, which are not Shh responsive—and which strongly overex-
press proteins due to episomal replication of the pCMV6 vector.
However, when expressed at more moderate levels in NIH 3T3
cells, cotransfection of DYRK2 resulted in loss of Gli2 (Figure 6A),
which could be prevented by the proteasome-inhibitor MG-132
(Figure 6B).
To test whether the kinases affected Gli2 activity by direct
phosphorylation, we first mapped the phosphorylation sites of
the kinases in Gli2. Purified MAP3K10 failed to phosphorylate
fragments of Gli2 expressed in E.coli, whereas purified DYRK2phosphorylated two conserved serines (Ser385 and Ser1011;
Figure S7) located in DYRK consensus sequences (Gwack
et al., 2006), as indicated by comparison of the results of kinase
assays using wild-type fragments and fragments where Ser385
and Ser1011 were mutated to alanine (Figure 6C). Mutation of
either of the sites had relatively little effect on the activity of
full-length Gli2 (not shown). However, simultaneous mutation
of both sites made Gli2 resistant to DYRK2, indicating that
DYRK2 affects Gli2 activity via phosphorylation of Ser385 and
Ser1011 (Figure 6D). These results indicate that DYRK2 directly
phosphorylates Gli2 and induces its degradation by the ubiqui-
tin-proteasome system (Figures 6B and 6D).
DISCUSSION
The Kinome Collection
We report here the molecular cloning of 93% of all human pro-
tein kinases identified in silico by Manning et al. (2002). We
further generate a catalytically inactive kinase collection. To-
gether, these collections represent the first high-confidence
set of cDNAs representing a large human gene family, and the
first systematic collection of functionally altered cDNAs. These
collections represent a unique resource for genome-wide stud-
ies of signal transduction and signaling crosstalk.
The vast majority (97%; 464/480) of the kinases were cloned
directly from human cDNA libraries, resulting in high-quality
collection without the mutant, truncated, and/or artifactual
clones that can result from the use of PCR or synthetic gene
technologies. Analysis of splice variants indicated that the col-
lection does not contain many truncated transcripts, and nearly
all (98.1%) known protein domains found in any splice variant
of the kinases were present in our collection. This is consistent
with our cloning strategy, which generally results in isolation of
the most commonly expressed transcript variant. These vari-
ants are the most desirable ones for purposes of functional
screening. However, due to the complexity of alternative splic-
ing of human genes, it is likely that many functionally important
splice variants of kinases will be identified. To facilitate such
analyses, splicing of the kinome needs to be analyzed carefully
using exon microarrays and/or transcript sequencing of all
human tissues.Cell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc. 543
Figure 5. DYRK2 and MAP3K10 Act at the Level of the GLI Transcription Factors
(A and B) Both DYRK2 and MAP3K10 affect activity of the Shh pathway in Smo (A) and SuFu (B) deficient cells indicating that they act downstream of SuFu. PKAa,
activated form of PKA. Assays were performed in the absence (white bars) and presence (gray bars) of ShhN. Error bars in all panels indicate 1 SD (n = 4).
(C) GLI2 with hyperactive transcriptional activator domain (GLI2-VP16) is resistant to MAP3K10 but not to DYRK2.
(D) DYRK2 but not MAP3K10 coexpression results in formation of slower migrating forms of GLI2 and GLI3. GLIs phosphorylated by activation of PKA by forskolin
(FSK) or FSK and IBMX are shown as control.
(E) DYRK2 but not MAP3K10 phosphorylates full-length Gli2 in vitro. Lower panel shows Gli2 protein loading. Note that the phosphorylation of Gli2 by DYRK2 also
results in a slower migrating form as in (D).
(F) Identification of protein-protein interactions and kinase substrates for MAP3K10. In vitro kinase and binding assays were performed using a protein array
containing 8265 human proteins. Multiple Hh pathway-related kinases (red diamonds) are among the 50 strongest binding partners (dotted line). Kif3A, a known
binding partner for MAP3K10, is also identified as a phosphorylated substrate (green diamond).
(G) MAP3K10 increases the in vitro kinase activity of GSK3b but not CK1a or CK13.
(H) DYRK2 is phosphorylated by MAP3K10 to two specific sites as identified by LC/MS. Note that the Thr308 is directly adjacent to the in vivo autophosphorylated
tyrosine (red) in DYRK2.Kinome Expression Screening
To demonstrate the utility of the resource, we used it in three
different kinome-wide screens, identifying two novel kinases
affecting Shh signaling and one kinase inducing reactivation of
a latent human tumor virus, KSHV. These analyses revealed
that cDNA expression screening is a powerful and specific
method for identification of novel regulators of signaling path-
ways.
Compared to loss-of-function analyses such as RNAi (Bjor-
klund et al., 2006; Gwack et al., 2006; Lum et al., 2003), the
gain-of-function approach described here can also be used to
identify kinases that are not expressed in the cell type tested,
act redundantly, or activate the pathways analyzed under path-544 Cell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc.ological conditions. In addition, the best models for different cel-
lular signaling events may not be derived from cells of human or-
igin, limiting the utility of human siRNA libraries. Such restriction
largely does not limit the use of human cDNA tools in cells from
other mammalian species, demonstrated here by the use of the
same kinome collection to study kinase signaling in mouse (Shh),
mink (TGFb), and monkey (KSHV) cells.
Identification of Kinases Regulating
Mammalian Hh Signaling
Using the kinome library we identified two novel kinases affect-
ing mammalian Shh pathway, MAP3K10 and DYRK2 (Figure 7).
The physiological significance of these findings is illustrated by
the facts that both kinases affected Shh signaling also in vivo
(Figure 4), and loss of Dyrk2 or Map3k10 function resulted in fail-
ure of Shh signaling (Figures 2C, 2D, and S2C). In contrast to
other signaling pathways where activation of pathway-specific
kinases is central to signal transduction, addition of Shh to
responsive cells did not appear to regulate the activity of
expressed DYRK2 or MAP3K10. This is consistent with the
lack of effect of Hh on activities of CK1a, CK13, GSK3b, and
PKA, known kinases whose activity is required for Hh signaling
in both Drosophila and mammals (Varjosalo and Taipale, 2007).
The mechanism by which the Shh signal is transduced thus
appears to depend on multiple relatively generic kinases, with
activity of the pathway likely controlled by access of these
kinases to pathway-specific substrate(s) (Figure 7).
In contrast to the nuclear kinase DYRK1, which has been re-
ported to activate GLI (Mao et al., 2002), we found that DYRK2
localizes to the cytoplasm and inhibits Shh signaling by decreas-
ing GLI activity. DYRK2 directly phosphorylated Gli2 sequences
and resulted in the loss of coexpressed GLI proteins, indicating
Figure 6. The Mechanisms of Action of
DYRK2 and MAP3K10
(A and B) DYRK2 but not MAP3K10 coexpression
induces degradation of GLI2 and GLI3 as indi-
cated by immunostaining (A) or western blotting
(B) of NIH 3T3 cells 2 days after transfection.
Note that MG132 treatment (6 hr) prevents GLI3
degradation (B).
(C) Purified DYRK2 phosphorylates two fragments
of GLI2, but fails to phosphorylate the same
fragments (arrows) where S385 and S1011 are
mutated to alanine. Note that purified MAP3K10
does not phosphorylate any of the GLI2 frag-
ments.
(D) GLI2 lacking the DYRK2 phosphorylation sites
(GLI2-S385, 1011A; 5% w/w DNA) is resistant to
effects of DYRK2 on its transcriptional activity
and protein level (inset). Error bars indicate 1 SD
(n = 4).
that DYRK2 acts by inducing the phos-
phorylation and degradation of GLI pro-
teins via the ubiquitin/proteasome path-
way (Figure 6).
The other kinase we identified,
MAP3K10, acts positively on the Shh
pathway by increasing the transcriptional
activator activity of GLI (Figure 5C).
MAP3K10 has previously been linked to
JNK (C-Jun N-terminal kinase) signaling
(Gallo and Johnson, 2002) and to regula-
tion of trafficking of clathrin-coated vesi-
cles (Akbarzadeh et al., 2002). The effect
of MAP3K10 on GLI2 appears not to be
direct. Instead, MAP3K10 binds to multi-
ple kinases regulating Shh pathway,
including CK1a, CK13, GSK3b, and
DYRK2. In addition, MAP3K10 has been
shown to associate with Kif3a (Nagata
et al., 1998), a component of cytoplasmic kinesin II, which is re-
quired for Shh pathway regulation in mice (Huangfu et al., 2003).
Our protein microarray experiments confirmed this finding and
further indicated that Kif3a is also a substrate for MAP3K10. Al-
though both MAP3K10 and DYRK2 act at the level of Gli2 but
with opposing effects, MAP3K10 action cannot be explained
solely by its effect on DYRK2, as these kinases have different
activity on Gli2-VP16 transcriptional activity (Figure 5C). Many
connections of MAP3K10 with different pathway components
suggest that MAP3K10 action on GLI2 is likely to be complex,
and its detailed dissection will require further mechanistic
studies.
Viral Reactivation Screen
Our kinome-wide ectopic expression screen identified PIM1 as
a novel kinase regulating the balance between latency and lytic
replication in KSHV-infected cells. PIM kinases have previously
been linked to regulation of viral oncogenesis. PIM1 and PIM2
have been suggested to promote EBV-induced immortalizationCell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc. 545
and tumorigenesis (Rainio et al., 2005), and PIM1 was proposed
to be involved in KSHV pathogenesis via its interaction and
phosphorylation of KSHV latency-associated nuclear antigen
(LANA-1) (Bajaj et al., 2006). We show here that viral reactivation
induces PIM1 expression and activity, resulting in LANA-1 bind-
ing to and phosphorylation by PIM1, and consequent conversion
of KSHV from latency to lytic replication.
The switch from latency to lytic replication is an elementary de-
cision in viral life cycle—especially in the case of herpes viruses.
Several lines of evidence support the importance of induction of
viral replication in herpes viral tumorigenesis (Grundhoff and
Ganem, 2004; Hayward et al., 2006). Hence, cellular signaling
pathways operative during viral reactivation could represent
potential novel targets for therapeutic intervention.
TGFb Screen
In TGFb screen we identified type I and type II receptors for
activin and TGFb, but did not find any novel kinases. This is
consistent with the fact that the TGFb pathway is relatively well
characterized and short – TGFb type I receptors directly phos-
phorylate the Smad transcription factors (Massague et al.,
2005). However, the clear identification of the TGFb receptors
in this screen establishes that overexpression screening is
a highly sensitive and accurate method in identifying critical
pathway components.
Signaling Crosstalk
Previous biochemical and genetic studies have revealed that in
addition to functioning on their specific pathways, many kinases
can also participate in crosstalk between signaling pathways
(e.g., Cully et al., 2006; Katz et al., 2007). However, signaling
crosstalk induced by overexpression has generally not been sys-
tematically analyzed. Our kinome screens, in fact, represent the
first genome-wide quantitative analyses of crosstalk between ki-
nase pathways. A large number of overexpressed kinases, which
normally function in their specific pathways, had statistically sig-
nificant effects in both the Shh and TGFb screens. These results
indicate that there can be extensive crosstalk between different
signaling pathways under pathological conditions where kinases
Figure 7. A Model of MAP3K10 and DYRK2 Function
Green and red colors indicate positively and negatively acting components of
the Shh pathway, respectively.546 Cell 133, 537–548, May 2, 2008 ª2008 Elsevier Inc.are overexpressed and/or strongly activated. In an analogous
manner, activation of signaling pathways controlling cell growth
by mutant kinases, which normally do not act on such pathways,
could explain the recent observations that an unexpectedly large
number of protein kinases are found to be mutated in human
cancer (Greenman et al., 2007).
The extensive crosstalk observed also explains the large num-
ber of published results where gain-of-function experiments have
suggested a role for specific proteins in different pathways, but
the corresponding loss-of-function experiments have failed
to corroborate the findings (e.g., Lange-Carter et al., 1993;
Lee et al., 1997; Merchant et al., 2005; Murone et al., 2000; Yan
et al., 1994; Yujiri et al., 2000). However, we find here that the
known kinases affecting a given pathway generally have a very
strong effect compared to the other kinases (see also Lange-
Carter et al., 1993; Yan et al., 1994; Yujiri et al., 2000), and thus
by analyzing a large set of gain-of-function experiments at the
same time, one can focus on the strongest effectorswhose effects
are more likely to be significant under physiological conditions.
EXPERIMENTAL PROCEDURES
Generation of Kinome-wide Expression-Ready cDNA Libraries
The full-length kinase cDNA clones were identified using sequencing of
800,000 random clones, followed by isolation of specific clones using
Rapid-Screen Arrayed cDNA Panels (He and Jay, 2001), and finally by PCR
(see Supplemental Experimental Procedures). To generate Gateway clones,
the ORFs were recombined to pDONR221 and sequence verified. The active
site residues (Table S2) were mutated using ‘‘quick-change’’ site-directed
mutagenesis (Stratagene).
Cell Culture and Transfection
Cells were cultured in DMEM containing 10% fetal bovine serum (Mv1Lu, 293-
ShhN, COS1, s4Smo/ [Varjosalo et al., 2006] and SuFu/ [Svard et al., 2006]
mouse embryonic fibroblasts) or 10% bovine calf serum (NIH 3T3 and
Shh-LIGHT2) and antibiotics. SuFu/ MEFs (SuFuMEF/E174-2/5) were from
R. Toftga˚rd. Transfection was performed according to manufacturers’ instruc-
tions; FuGene6 was used for NIH 3T3, Vero, SuFu/ and s4Smo/ cells, Hi-
Perfect for Shh-LIGHT2, and JetPEI for COS1 cells. Chicken embryos were
electroporated (Intracel TSS20 Ovodyne; 30 V pulses for 5 3 50 ms at 4 mm
electrode distance) at Hamburger-Hamilton stage 11 and fixed by PFA after
42–48 hr (stage 18 and 19).
Screening and Data Analysis
All screens were performed on 96-well plate format. Luciferase-reporter
screening was performed in NIH 3T3 cells (Shh) or Mv1Lu cells (activin/TGFb)
essentially as described (Dennler et al., 1998; Taipale et al., 2002), using 50
ng of kinase constructs and 50 ng of reporters (1:19 mix of control to pathway
reporter) per well. pRL-SV40 (Promega) was used as a control reporter, and
Gli-Luc (Taipale et al., 2002) and pCAGA-Luc (Dennler et al., 1998) were used
as specific reporters for Shh and activin/TGFb pathway, respectively. After
1 day (activin/TGFb) or 2 days (Shh) transfection using FuGENE 6, cells were
stimulated with TGFb3 (5 ng/ml; a kind gift from Dr. Peter ten Dijke) or ShhN
(from 293-ShhN cell-conditioned medium [Chen et al., 2002], 1:10 v/v) in me-
dium containing 0.5% serum. After 16 hr (activin/TGFb) or 2 days (Shh), firefly
and Renilla luciferase activities were determined using the dual-Luciferase kit
(Promega; BMG FLUOstar OPTIMA Luminometer), followed by subtraction of
background luminescence counts from untransfected cells. Relative luciferase
activities were calculated by dividing the pathway-specific firefly luciferase
counts by the control Renilla luciferase counts separately for all replicates,
and sample mean and SD were calculated from these values (n = 3).
Constructs that caused a severe drop in Renilla luciferase counts (Tables S3
and S5) were classified as toxic and were not analyzed further. The high and
low value ranges (±3 SD) that should contain less than one kinase sample if no
kinases were active was determined by including multiple control samples ex-
pressing GFP (pEGFP-C1).
Four siRNAs from QIAGEN mouse kinome siRNA set v 1.0 targeting the
same kinases were pooled and transfected to Shh-LIGHT2 reporter cells. After
2 days, the cells were treated or not with conditioned medium containing Shh,
and luciferase activities measured after 60 hr.
For the viral-reactivation screen, Vero cells infected with rKSHV.219 virus
were transfected with individual kinase cDNAs. After 48 hr, the cells were
treated with recombinant baculovirus (BacK50) expressing the KSHV lytic
activator ORF 50 (RTA; a gift from J. Vieira) for 2 hr. For positive control of max-
imal reactivation, the cells were treated with 1.25 mM sodium butyrate (Sigma).
After 30 hr, the cells were fixed with PFA and RFP intensity was analyzed by
Cellomics Arrayscan 4.5 microscope.
For analysis of kinase expression, data from HG-U133a Affymetrix human
gene-expression microarray analyses were collected from GeneExpression
Omnibus, ArrayExpress, and scientific journals, and the data integrated and
normalized to ensure comparability (S.K. and O.K., unpublished data).
Immunochemistry, Fluorescence Microscopy, and Kinase Assays
Antibodies used are described in Supplemental Experimental Procedures. For
immunoblotting, samples were transferred to nitrocellulose, blocked,
incubated with anti-V5 (tagged kinases) or anti-Myc-epitope (Myc-GLI3 fusion
protein) antibodies, followed by HRP-conjugated secondary antibodies and
chemiluminescent detection (Amersham ECL).
For immunochemistry, PFA-fixed cells in microwell plates (Perkin Elmer
Viewplate) and 10 mm cryosections were incubated with the indicated anti-
bodies followed by Alexa594-conjugated secondary antibodies. Fluorescent
fusion proteins expressed in NIH 3T3 cells grown on fibronectin-coated cover-
slips (BD Biosciences) were observed 2 days after transfection. Imaging was
performed using Cellomics Arrayscan, Zeiss AxioplanII, or Zeiss LSM510
Meta confocal microscopes.
ProtoArray v 4.0 arrays were used for protein array-based interaction and ki-
nase assays (Invitrogen). In-solution kinase assays were performed using puri-
fied E. coli expressed DYRK2-MBP or insect cell expressed MAP3K10-GST,
CK1a-GST, CK13-His6, and GSK3b-His6 (Invitrogen) fusion proteins and puri-
fied casein, TAP-Gli2orGST-Gli2 fragmentsubstrates (see SupplementalExper-
imental Procedures). Samples were incubated for 1 hr at 30C, separated by
SDS-PAGE, transferred tonitrocellulose,and exposed toHypermax MRfilm(Ko-
dak). For LC/MS analyses, substrates were separated by SDS-PAGE, and tryp-
sin digested, followed by enrichment of phosphorylated peptides by TiO2 beads
(Thingholm et al., 2006) and analysis by nanoLC FT-MS (Thermo Electron).
SUPPLEMENTAL DATA
Supplemental Data include seven figures, seven tables, Supplemental Exper-
imental Procedures, Supplemental References, and a Supplemental Database
and can be found with this article online at http://www.cell.com/cgi/content/
full/133/3/537/DC1/.
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